Zydus Lifesciences Makes Bold MedTech Leap with €256.8 Million Amplitude Surgical Acquisition

Zydus Lifesciences Ltd. has officially completed its landmark block acquisition of Amplitude Surgical SA, a French leader in lower-limb orthopaedic technologies. The deal, finalized on July 29, 2025, marks Zydus’ most significant international expansion in the MedTech space and sets the stage for a full takeover of the Paris-listed company.

Key Developments from the Block Acquisition

Zydus acquired 85.6 percent of Amplitude Surgical’s share capital and voting rights

The acquisition was executed at €6.25 per share, totaling €256.8 million

The deal was structured through the purchase of shares from PAI Partners and two minority shareholders

All regulatory and contractual conditions were fulfilled prior to closing

This strategic move positions Zydus as a major player in the global orthopaedic surgical market, expanding its footprint beyond pharmaceuticals into high-value medical devices.

Strategic Intent and Future Roadmap

Simplified Tender Offer and Squeeze-Out Plans

Zydus will file a mandatory simplified tender offer on July 30, 2025, for the remaining shares of Amplitude Surgical

The offer will match the acquisition price of €6.25 per share

With commitments from seven minority shareholders representing 4.7 percent of capital, Zydus is poised to cross the 90 percent ownership threshold

Upon completion, Zydus intends to initiate a squeeze-out procedure to acquire full control

Leadership Continuity and Operational Stability

Olivier Jallabert will continue as CEO of Amplitude Surgical

As part of the transaction, Jallabert has reinvested in the company, reinforcing management alignment

Amplitude Surgical terminated its liquidity contract with Oddo BHF and Natixis effective July 28, 2025

Regulatory and Market Implications

The tender offer is subject to clearance by the French Financial Market Authority (AMF)

No additional regulatory approvals are required, streamlining the path to full acquisition

The offer is expected to open in September 2025, pending AMF approval

This acquisition is expected to be transformative for Zydus, enabling it to diversify revenue streams and leverage Amplitude’s innovation pipeline.

Financial and Strategic Impact

Amplitude Surgical reported revenue of nearly €111 million as of June 30, 2025

The company employs 429 people and operates in over 30 countries

Zydus’ acquisition provides access to proprietary technologies in hip and knee surgery

The deal aligns with Zydus’ broader strategy to build a global MedTech platform

Amplitude’s strong presence in Europe and its innovation-led approach make it a valuable asset for Zydus’ long-term growth ambitions.

Market Sentiment and Investor Takeaways

The acquisition signals Zydus’ intent to become a diversified healthcare conglomerate

Investors may view the move as a strategic hedge against pharma sector volatility

The transaction could unlock synergies in R&D, distribution, and regulatory pathways

Zydus’ shares are expected to reflect positive momentum as the company integrates Amplitude Surgical and prepares for the next phase of its MedTech journey.

Conclusion

Zydus Lifesciences’ completion of the Amplitude Surgical block acquisition marks a pivotal moment in its evolution from a pharmaceutical powerhouse to a global healthcare innovator. With a simplified tender offer on the horizon and full control within reach, Zydus is poised to redefine its role in the surgical technology space.

Source: BusinessWire – July 29, 2025 FinanzWire – July 29, 2025 Express Pharma – July 29, 2025 CNBC TV18 – July 29, 2025 Indian Pharma Post – July 29, 2025